A ims: Fontan failure (FF) represents a growing and challenging indication for pediatric orthotopic heart transplantation (OHT). The aim of this study was to identify predictors of best midterm outcome in OHT after FF.
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Introduction S ince its original description over 40 years ago, the Fontan operation 1 has undergone countless modifications, probably like no other procedure in pediatric cardiac surgery. Despite the excellent results that can be currently expected for modern Fontan completion 2,3 , there are still concerns regarding the early and long-term durability of a circulation driven by a single ventricle 4 . Early Fontan failure (FF), although rare, is not a completely resolved clinical issue 5 . A large variety of other Fontan-specific complications including protein-losing enteropathy (PLE), plastic bronchitis, intractable arrhythmias, thrombosis or obstruction in the Fontan circuit, among others, can lead to the failure of the Fontan principle, even in the presence of a relatively normal function of the single ventricle 6 . Fontan revision or conversion can address residual anatomic lesions or control focal atrial arrhythmias 7 . Catheter-based interventions and pharmacologic manipulation of pulmonary vascular resistance 8 can provide additional treatments, aiming at the best energy preservation model. Nevertheless, primary myocardial dysfunction or intolerance of the Fontan circulation in the absence of correctable lesions, represent a growing indication for orthotopic heart transplantation (OHT) 9 . A previous Fontan status has been associated with lower actuarial survival after OHT, compared with non-Fontan congenital heart disease 10, 11 . Single center experience with OHT for FF is limited, and random variations in small cohorts might explain the non-uniform results of OHT after FF, mainly related to differences in early OHT outcome 11 . Therefore in 2012, the European Congenital Heart Surgery Association (ECHSA) conducted a study merging the databases of 22 ECHSA centers. The objective of this paper was to review the ECHSA experience with OHT after FF, evaluating outcome and possibly identifying the best FF candidate for OHT.
Methods
A retrospective multicenter study was conducted among 11 ECHSA centers in Europe and USA on the management of the FF circulation by OHT. Patients who developed FF after Fontan completion and underwent OHT as the ultimate surgical treatment of their FF status between 1991 and 2011 fulfilled the inclusion criteria and qualified for the present multicentre study. The closing date for follow-up was 31 December 2012. Review of medical records was approved by each local committee and single-institutional review board on clinical investigation. Individual patients were not identified, and the need for patient consent was waived. The contribution of individual centers over time is outlined in supplementary figure 1. A common ECHSA database was created summarizing baseline anatomical and demographic data of OHT recipients, technical details of previous palliative procedures, type of original Fontan operation, presence of fenestration, strategy of staged versus direct Fontan completion, previous Fontan conversion or take-down, timing of Fontan completion, timing and mechanism of FF and haemodynamic and echocardiographic data. Pre-transplant ventricular function was systematically evaluated by 2D echocardiography, and graded in a semiquantitative fashion as normal, moderately impaired or poor. This assessment was necessary due to the well-known variability in ventricular morphology of single ventricles, which prevented a systematic quantitative evaluation of ventricular function. Preoperative, intra-operative and postoperative variables, including pre-and post-OHT use of assist devices or extracorporeal membrane oxygenation (ECMO) were acquired. Early FF was prespecified and defined as the need for OHT within 2 years after the original Fontan completion. All FF requiring OHT later than 2 years after Fontan completion were defined as late FF. The 2-year time interval was selected to avoid colinearity with acute FF and emergency OHT. The primary end-points of the study were death and reintervention after OHT for FF. The secondary endpoints related to quality of life in terms of functional class and major transplant-specific morbidity. Hospital chart review was conducted for each transplant recipient and donor at the local Institution. The University Medical Center of Groningen coordinated the study, collected the data, maintained the database and performed all the data analysis.
Statistical analysis
Standard summary statistics were reported as mean and standard deviation for normally distributed continuous variables, while median with range were used for skewed continuous variables. Categorical analysis was conducted by Fisher-exact testing, while continuous variables were compared by unpaired t-testing. Analysis of freedom from events (death and reintervention) was conducted by Kaplan-Meier (KM) technique at 3 months, 1 year, 5 years and 10 years after OHT; Wilcoxon and log-rank testing were utilized to compare event-free survival between subgroups. Cumulative hazards were calculated for each event-free survival. All potential risk factors for 5-year mortality were first assessed by logistic regression analyses and then entered in a multivariate Cox proportional hazard model to identify independent predictors of 5-year mortality, checking for the Institutions  189 proportionality assumption. A p-value less that 0.05 was considered significant. Statistical analysis was conducted with the SAS-statview 1998 statistical software, SAS Institute Inc, NC, USA.
Supplementary figure 1. Contribution of individual centers over time

Results
B etween 1991 and 2011, 61 patients underwent OHT for FF at 11 ECHSA centers.
The cohort includes 51 primary OHT for FF, 6 OHT for FF after Fontan conversion and 4 OHT after Fontan take-down. Mean age at OHT was 15.0 ± 9.7 years. Seven patients (11.4%) were younger than 6 years of age at OHT. Male gender was prevalent (39 patients, 63.9%). The majority of OHT were performed after 2001 (48 OHT=78.6%). Total follow-up was 339.7 patient/years. Mean follow-up was 66.8 ± 54.2 months (range: 12.1 to 254 months) and was 100% complete and updated.
Baseline anatomy and surgical history
The anatomic details of the cohort are depicted in table 1. Surgical revision of Fontan 3 PA branch stenting prior to OHT 6 Other catheter intervention prior to OHT 9 an extracardiac Fontan had been accomplished in 6 patients 3.7 ± 0.9 years prior to OHT, surgical revision of a suboptimal Fontan pathway had been performed in 3 patients 2.6 ± 1.1 prior to OHT, while Fontan takedown had been necessary in 4 pts 10.1 ± 6.6 months prior to OHT. The mean time interval between Fontan completion and OHT was 10.7 ± 6.6 years. Early FF represented the indication for OHT in 11 patients (18%). The mean time interval between Fontan completion and OHT was 0. 8± 0.5 years in early FF and 10.5 ± 6 years in late FF (p < 0.001). Table 3 summarizes the baseline characteristics of early and late FF subgroups. There was no significant difference between early FF and late FF according to sex, primary diagnosis, BDG staging, age at Fontan, presence of fenestration, indication for OHT, time on waiting list, need for pretransplant ICU admission, mechanical ventilation, dialysis or mechanical support.
OHT Indication and hemodynamics
The main indication for OHT included intractable arrhythmias (9 pts =14.8%), thrombosis or complex obstruction of the Fontan circuit up to the level of the pulmonary veins (10 pts= 16.4%), PLE (14 pts=22.9%), primary chronic ventricular failure (19 pts=31.1%), or a combination of the above (9 pts=14.8%). Arrhythmias included atrial fibrillation (7) and nonsustained ventricular tachycardia (2) refractory to medical therapy and/or catheter intervention. Arrhythmias were significantly more common in atriopulmonary Fontan (6/17 pts= 35.2%) than in TCPC (3/44 pts= 6.8%) (p-value=0.010). Two patients with Fontan pathway obstruction presented concomitant aortic arch obstruction resilient to catheter intervention. Severe AV valve insufficiency was diagnosed in 16 pts (26.2%). Ventricular function by two-dimensional echocardiographic evaluation was defined as "poor" in 43 patients (70.5%), while normal or moderate dysfunction was detected in 18 patients (29.5%). Table 3 shows that impaired ventricular function was diagnosed in 80% late FF (40/50 pts) and in only 27.2% early FF (3/11 pts, p-value= 0.0014). The mean pre-transplant pulmonary artery pressure (PAP) was 19.7 ± 3.7 mmHg with a mean transpulmonary gradient of 7.1 ± 1.2 mmHg and a mean end-diastolic ventricular pressure (EDVP) of 12.6 ± 1.1 mmHg. PVR index was measured in 11 pts (18%) prior to OHT and calculated equal to 2.96 ± 0.99 Wood Units/m 2 , however, in the setting of extensive aortopulmonary collateral flow, this calculation should be considered with caution.
Status at OHT
The mean number of days on the waiting list was 51.6 ± 37.0. The mean New York Heart Association (NYHA) class prior to OHT was 3.38 ± 0.62. Seventeen pts (27.8%) were in high urgency status, all admitted in the ICU on inotropic support for a mean of 33.6 ± 12.6 days. Prior to OHT, mechanical ventilation was necessary in 6 (9.8%) and hemodialysis in 3 (4.9%). Two patients were successfully bridged to OHT by a paracorporeal ventricular assist device (Berlin Heart EXCOR pediatric VAD, Berlin, Germany) either as LVAD interposed between the common atrium and the neoaorta (1 pt) or as RVAD interposed between the systemic venous return and the pulmonary arteries (1 pt). The first patient received an OHT two days after LVAD implant while the latter was bridged to OHT for 408 days and is currently alive and well 5 years after OHT Plasmapheresis was used in 15 patients (24.5%) in the treatment of antibody-mediated rejection and combined with immunoadsorption in 4 cases with elevated panel reactive antibody. The mean time of mechanical ventilation after OHT was 8.2 ± 2.7 days in the overall cohort, and 4.8 ± 1.9 days in hospital survivors. The mean ICU stay was 22.6 ± 6.8 days and the mean hospital stay was 45.7 ± 9.6 days.
Late outcome
Late mortality (after hospital discharge) was 14% (7/50 pts) and occurred between 1.1 and 19.1 years after OHT. Four deaths (57.1%) supervened between 0.6 and 26.4 months after re-OHT. Causes of late death included cancer in 2, mycotic infections in 2, acute rejection (1), chronic rejection (1) and multiorgan failure after re-OHT (1). Lymphoproliferative disorder was the cause of death in one patient 55 months after OHT. This patient had developed recurrent PLE 33 months after OHT and was bridged by ECMO to successful re-OHT, but eventually died 22 months later for B-cell lymphoma. Uterine cancer was the cause of death in one patient 19.1 years after OHT and 3.2 years after re-OHT for chronic rejection. Two lethal mycotic infections occurred at 47 and 97 months after OHT. An Aspergillus fumigatus brain abscess was the cause of death in one patient 8.1 years after ABO incompatible OHT, treated until then with column-based immunoabsorption, exchange plasmapheresis, C1 inhibitor infusion and subsequent triple immunosuppressive regimen. 0  24  48  72  96  120 Months  50  43  37  35  31  20  11  8  6  5  4  3 196 A Candida septicemia was the cause of death in another patient 1.1 month after re-OHT performed 3.9 years after OHT. Acute rejection with severe myocardial necrosis was the cause of death in one patient 45 months after OHT, while chronic rejection determined the death of a patient 9.1 years after OHT. Graft failure with subsequent multiorgan failure was the leading cause of death in the last patient, 18 days after re-OHT performed 88 months after his initial OHT. Overall Kaplan-Meier survival estimate was 81.9 ± 1.8% at 1 year, 73 ± 2.7% at 5 years and 56.8 ± 4.3% at 10 years after OHT (figure 1). (Figure 2 ).
Supplementary table 1. Kaplan Meier survival at 1 and 5 years after OHT according to mutually exclusive subgroups
When timing to FF was stratified by pre-OHT ventricular function, late FF with poor ventricular function exhibited the best mid-term outcome for OHT in FF, with 91.5 ± 5. Logistic regression identified potential risk factors for mortality that are outlined in Supplementary table 2 . When all potential risk factors for death (p < 0.10) were entered in a Cox proportional hazard model, early FF (p=0.0005), complex obstruction of Fontan pathway (p=0.0043) and PLE (p=0.0033) were identified as independent predictors of 5-year mortality ( Table 4 ).
Reintervention and major morbidity
Ten patients underwent major reinterventions between 0.4 and 180 months after OHT. Early graft failure (1), recurrent PLE (1) and chronic rejection (6) represented the indication for re-OHT in 8 patients. Candida mediastinitis with aortic penetration resulted in massive mediastinal bleeding in one patient who required multiple sternal revisions, excision of the infected tissue and patch reconstruction of the ascending aorta, 25 days after OHT. The last patient required stenting of the right pulmonary artery to correct a critical RPA stenosis 13 days after OHT. Additional reinterventions included re-exploration for bleeding (4), wound debridment (1) and embolization of a residual AV fistula (1) . KM freedom from major reintervention was 82.2±7% at 10 years. Five non-fatal but life-threatening infections were successfully treated 
Discussion
I n recent years there has been a growing interest for the challenging management of the FF circulation, which is expected to become a substantial cause of pediatric and adult congenital heart failure in the near future [12] [13] [14] . Several medical, surgical and catheterbased interventions have been introduced to improve the FF circulation, nevertheless OHT currently represents the ultimate surgical option in FF 15 . OHT in FF is still challenging for the complexity of preoperative, intraoperative and postoperative management. Our 18.3% early mortality favorably compares with the average early mortality on OHT for FF of most recent reports, which can vary from the outstanding 4% by the Atlanta group 16 , to 24% in St Louis report 17 , or to 35%, in the Columbia University experience 18 . Random variations in small and single-center cohorts over a long time span, may account for such a large variability in early outcome, nevertheless a 22% mean early mortality for OHT in FF was confirmed in three large multicenter studies 10, 11, 19 . Surgical creativity has largely overcome the technical intraoperative issues related to abnormalities of cardiac position, situs and systemic or pulmonary venous connections. The extensive use of donor tissue has proved to be useful in compensating for recipient anatomic defects or distorsions. This has been true in our experience as well, since virtually all our patients required extensive PA reconstruction and/ or systemic venous reconnection or systemic arterial remodeling preferentially by donor tissue. Moreover, we verified that previous conversion of an atriopulmonary Fontan to TCPC did not carry any additional risk at OHT. Despite the undeniable technical challenges, demonstrated by longer ischemic times and occasional need for circulatory arrest, a careful surgical planning enables a successful OHT for FF. The advancements in postoperative ICU care and immunosuppression therapies have further contributed to better survival trends in recent years [16] [17] [18] . These operative and postoperative improvements, however, did not translate into a statistically significant better early outcome in recent years, both in single center reports, 18, 20 and in multicenter studies 13 11 . Nevertheless this impact was completely neutralized when conditional freedom from death was analyzed for 90day survivors. We infer that substantial improvements in the early phase of hazard after OHT for FF might be achieved when properly addressing pre-transplant issues, since operative and postoperative enhancements were not sufficient to abolish the gap with non-Fontan congenital OHT outcome. This issue guided the rationale of our multicenter study, which was specifically designed to identify the best candidate for OHT in FF, in order to set the optimal standards for early and mid-term OHT survival. Our multicenter study proves that primary ventricular failure represents the best indication for OHT in FF, in agreement with the experience of Griffiths et al. 6 . Poor ventricular function was identified as an inverse risk factor of 5-year mortality. We could verify a strong correlation between late FF and impaired ventricular function. We observed that patients with late FF and poor ventricular function can benefit the most from OHT, exhibiting a 91.5±5.8% 5-year OHT survival. These two last findings represent the novel message of this report, which centers on the domain of best graft allocation in OHT for FF. Referral for OHT in this setting should occur prior to the development of systemic hypoperfusion, severe malnutrition or cachexia. Conversely, several risk factors for OHT mortality have been suggested in previous studies. Bernstein et al. identified younger age and need for mechanical ventilation at listing as significant preoperative risk factors for OHT in FF 10 . Davies et al. indicated higher creatinine levels prior to OHT as an independent predictor of mortality 18 . In our study, anatomic diagnosis including heterotaxy, ICU admission with pre-OHT inotropic support and mechanical ventilation did not affect OHT outcome, in agreement with the experience of Backer et al 20 .
High pre-OHT pulmonary artery pressures only marginally influenced 5-year OHT survival by univariate analysis. Need for dialysis after OHT was associated with a significant increase in 5-year mortality by univariate analysis, in agreement with Davies et al 18 . Our multivariate analysis indicates early FF as the most powerful predictor of 5-year OHT mortality. Early FF was associated with a relatively preserved ventricular function. OHT for early FF and preserved ventricular function was not beneficial in our experience, because the problem was not myocardial in origin. We believe that alternative options such as Fontan revision or take-down 5 should be pursued in this scenario. Moreover we speculate that RVAD could be considered in selected cases, as we could successfully bridge to OHT early FF with preserved ventricular function, after resolution of PLE through RVAD 22 . This study identified PLE as an independent predictor of OHT mortality, mainly for infective complications, but we acknowledge that PLE was cured in the majority of our OHT survivors, as reported by Backer et al 20 .
One of the strengths of this study is it multi-institutional nature is, which reflects a crosssection of contemporary practice of OHT in FF, as demonstrated by the high percentage of HLHS and variants in the anatomic spectrum, by the mean age at Fontan completion, the high prevalence of TCPC as technique for Fontan completion and the uniform bicaval technique used for OHT. Nevertheless this is a retrospective study and selection bias related to indication for listing and transplant might have occurred among different institutions. Moreover, this report does not evaluate the morbidity and mortality which occurred on the waiting list, possibly introducing additional selection bias.
In conclusion, OHT is an excellent option for late FF with impaired ventricular function. Previous Fontan conversion does not jeopardize subsequent OHT. Early FF is the most powerful predictor of 5-year mortality after OHT. This finding underlines the magnitude of the decision-making process at the time of Fontan completion, since rescue OHT after early FF seems unwarranted. PLE improves in the majority of patients after OHT, but remains an independent predictor of mortality, mainly for the exposure to early infection hazard.
